The evaluating prescription opioid changes in veterans (EPOCH) study: Design, survey response, and baseline characteristics.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read Online Read More Add to Saved list
  • Additional Information
    • Source:
      Publisher: Public Library of Science Country of Publication: United States NLM ID: 101285081 Publication Model: eCollection Cited Medium: Internet ISSN: 1932-6203 (Electronic) Linking ISSN: 19326203 NLM ISO Abbreviation: PLoS One Subsets: MEDLINE
    • Publication Information:
      Original Publication: San Francisco, CA : Public Library of Science
    • Subject Terms:
      Analgesics, Opioid* ; Surveys and Questionnaires*; Drug Prescriptions/*statistics & numerical data ; Veterans/*statistics & numerical data; Cohort Studies ; Female ; Humans ; Male ; Middle Aged ; Self Report
    • Abstract:
      In the United States (US), long-term opioid therapy has been commonly prescribed for chronic pain. Since recognition of the opioid overdose epidemic, clinical practice guidelines have recommended tapering long-term opioids to reduced doses or discontinuation. The Effects of Prescription Opioid Changes for veterans (EPOCH) study is a national population-based prospective observational study of US Veterans Health Administration primary care patients designed to assess effects of evolving opioid prescribing practice on patients treated with long-term opioids for chronic pain. A stratified random sampling design was used to identify a survey sample from the target population of patients treated with opioid analgesics for ≥ 6 months. Demographic, diagnostic, visit, and pharmacy dispensing data were extracted from existing datasets. A 2016 mixed-mode mail and telephone survey collected patient-reported data, including the main patient-reported outcomes of pain-related function (Brief Pain Inventory interference; BPI-I scores 0-10, higher scores = worse) and health-related quality of life. Data on survey participants and non-participants were analyzed to assess potential nonresponse bias. Weights were used to account for design. Linear regression models were used to assess cross-sectional associations of opioid treatment with patient-reported measures. Of 14,160 patients contacted, 9253 (65.4%) completed the survey. Participants were older than non-participants (63.9 ± 10.6 vs. 59.6 ± 13.0 years). The mean number of bothersome pain locations was 6.8 (SE 0.04). Effectiveness of pain treatment and quality of pain care were rated fair or poor by 56.1% and 45.3%, respectively. The opioid daily dosage range was 1.6 to 1038.2 mg, with mean = 50.6 mg (SE 1.1) and median = 30.9 mg (IQR 40.7). Among the 73.2% of patients who did not receive long-acting opioids, the mean daily dosage was 30.4 mg (SE 0.6) and mean BPI-I was 6.4 (SE 00.4). Among patients who received long-acting opioids, the mean daily dosage was 106.2 mg (SE 2.8) and mean BPI-I was 6.8 (SE 0.07). Higher daily dosage was associated with worse pain-related function and quality of life among patients without long-acting opioids, but not among patients with long-acting opioids. Future analyses will use follow-up data to examine effects of opioid dose reduction and discontinuation on patient outcomes.
      Competing Interests: The authors have declared that no competing interests exist.
    • References:
      Pain. 2014 May;155(5):843-4. (PMID: 24508716)
      J Pain. 2018 Sep;19(9):1082-1090. (PMID: 29715520)
      Qual Life Res. 2009 Feb;18(1):43-52. (PMID: 19051059)
      Clin J Pain. 2010 Nov-Dec;26(9):763-9. (PMID: 20842015)
      J Pain. 2017 Apr;18(4):437-445. (PMID: 27993558)
      JAMA. 2018 Apr 10;319(14):1444-1472. (PMID: 29634829)
      Pain. 2014 Nov;155(11):2337-43. (PMID: 25180008)
      JAMA Intern Med. 2015 Apr;175(4):608-15. (PMID: 25686208)
      Pain Med. 2015 Sep;16(9):1745-58. (PMID: 26011277)
      J Pain. 2017 Nov;18(11):1365-1373. (PMID: 28690000)
      J Pain. 2019 Feb;20(2):146-160. (PMID: 30096445)
      J Pain. 2019 Feb;20(2):181-191. (PMID: 30243859)
      Pharmacoepidemiol Drug Saf. 2018 May;27(5):526-534. (PMID: 28879660)
      J Pain. 2016 Oct;17(10):1068-1080. (PMID: 27377620)
      Pain. 2015 Feb;156(2):231-42. (PMID: 25599444)
      Pain. 2016 Apr;157(4):849-57. (PMID: 26785321)
      JAMA. 2018 Dec 18;320(23):2448-2460. (PMID: 30561481)
      Med Care. 2005 Nov;43(11):1130-9. (PMID: 16224307)
      Pain Med. 2016 Oct;17(10):1838-1847. (PMID: 27207301)
      J Gen Intern Med. 2018 Jun;33(6):818-824. (PMID: 29380212)
      Arch Intern Med. 1998 Mar 23;158(6):626-32. (PMID: 9521227)
      Clin J Pain. 2010 Jul-Aug;26(6):489-97. (PMID: 20551723)
      MMWR Recomm Rep. 2016 Mar 18;65(1):1-49. (PMID: 26987082)
      JAMA. 2011 Apr 6;305(13):1315-21. (PMID: 21467284)
      J Pain. 2004 Mar;5(2):133-7. (PMID: 15042521)
      J Am Board Fam Med. 2014 May-Jun;27(3):329-38. (PMID: 24808111)
      PLoS One. 2013 Dec 02;8(12):e80095. (PMID: 24312456)
      J Gen Intern Med. 2006 Mar;21(3):267-75. (PMID: 16336622)
      Pain. 2011 Jun;152(6):1249-55. (PMID: 21397401)
      Pain. 2011 Jun;152(6):1256-62. (PMID: 21296498)
      Clin J Pain. 2004 Sep-Oct;20(5):309-18. (PMID: 15322437)
      Pain. 2006 Nov;125(1-2):172-9. (PMID: 16842922)
      J Pain. 2015 Apr;16(4):318-25. (PMID: 25486625)
    • Grant Information:
      I01 HX001752 United States HX HSRD VA; IK2 HX001914 United States HX HSRD VA; F30 AT009162 United States AT NCCIH NIH HHS
    • Accession Number:
      0 (Analgesics, Opioid)
    • Publication Date:
      Date Created: 20200423 Date Completed: 20200702 Latest Revision: 20210826
    • Publication Date:
      20231215
    • Accession Number:
      PMC7176145
    • Accession Number:
      10.1371/journal.pone.0230751
    • Accession Number:
      32320421